Syros Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$2.68K
-0.0
-1.01
68
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is actively engaged in the voluntary delisting process. The firm was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is actively engaged in the voluntary delisting process. The firm was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Recently from Cashu
Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals to Enhance Kidney Disease Therapies
Rege Nephro Expands Clinical Horizons with Acquisition of Tamibarotene Assets from Syros Pharmaceuticals Rege Nephro Co., Ltd., a clinical-stage biotechnology company based in Kyoto, Japan, strengthen…
Rege Nephro Acquires Tamibarotene from Syros Pharmaceuticals to Enhance Kidney Disease Treatments
Rege Nephro Expands Clinical Portfolio with Acquisition of Tamibarotene from Syros Pharmaceuticals In a significant development within the biotechnology sector, Rege Nephro Co., Ltd., based in Kyoto,…
Kia Syros SUV Launch: A Family-Friendly Vehicle for India's Evolving Automotive Market
Kia Syros SUV Launch: A New Era for Family-Oriented Vehicles in India Kia India officially launches the Kia Syros SUV, targeting the family-oriented segment of the Indian automotive market. Following…
Syros Pharmaceuticals Awaits Key SELECT-MDS-1 Trial Results for Tamibarotene in HR-MDS Treatment
Syros Pharmaceuticals Prepares for Critical Trial Results in MDS Treatment Syros Pharmaceuticals, a biopharmaceutical company dedicated to advancing therapies for hematologic malignancies, is on the b…